Vera Therapeutics, Inc.
VERANasdaqCIK 1831828HealthcareFiscal year ends Dec 31
Reports and events: 107 filings
Newest first, by EDGAR acceptance time (Eastern). Each filing’s page lists its documents on sec.gov and, for 10-K and 10-Q reports, the extracted sections.
What the forms are: 10-K, 10-Q, 8-K, Form 4, DEF 14A, Schedule 13D, Schedule 13G, amendments, accession numbers.
| Filed | Form | What it is | Accession number |
|---|---|---|---|
| 2026-09-1506:45 ET | 8-K | 7.01 Regulation FD disclosure; 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-26-391280 |
| 2026-08-1016:10 ET | 10-Q | Quarterly reportPeriod 2026-06-30 | 0001193125-26-342380 |
| 2026-08-1016:05 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-26-342335 |
| 2026-07-0908:00 ET | 8-K | 5.02 Departure or appointment of officers or directors | 0001193125-26-299165 |
| 2026-07-0712:45 ET | 8-K | 8.01 Other events | 0001193125-26-297211 |
| 2026-06-0207:05 ET | 8-K | 8.01 Other events | 0001193125-26-252475 |
| 2026-05-2616:54 ET | 8-K | 5.07 Shareholder vote results | 0001193125-26-239559 |
| 2026-05-0716:33 ET | 10-Q | Quarterly reportPeriod 2026-03-31 | 0001193125-26-212143 |
| 2026-05-0707:30 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-26-210351 |
| 2026-04-0916:05 ET | DEF 14A | Proxy statementPeriod 2026-05-21 | 0001140361-26-014002 |
| 2026-03-0917:01 ET | 8-K | 5.02 Departure or appointment of officers or directors | 0001193125-26-098783 |
| 2026-03-0506:11 ET | SCHEDULE 13D/A | Ownership report, active investor, amended | 0001104659-26-023756 |
| 2026-02-2617:25 ET | 10-K | Annual reportPeriod 2025-12-31 | 0001193125-26-077442 |
| 2026-02-2607:30 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-26-073421 |
| 2025-12-1819:50 ET | 8-K | 5.02 Departure or appointment of officers or directors | 0001193125-25-323298 |
| 2025-12-1017:18 ET | 8-K | 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-25-314430 |
| 2025-11-2616:30 ET | 8-K | 5.02 Departure or appointment of officers or directors | 0001193125-25-300647 |
| 2025-11-0609:59 ET | 8-K | 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-25-268331 |
| 2025-11-0516:06 ET | 10-Q | Quarterly reportPeriod 2025-09-30 | 0001193125-25-266881 |
| 2025-11-0508:00 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-25-265799 |
| 2025-08-0516:56 ET | 8-K | 1.01 Entry into a material agreement; 1.02 Termination of a material agreement; 9.01 Financial statements and exhibits | 0001193125-25-173591 |
| 2025-08-0516:06 ET | 10-Q | Quarterly reportPeriod 2025-06-30 | 0000950170-25-103022 |
| 2025-08-0507:30 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0000950170-25-102399 |
| 2025-06-0306:36 ET | 8-K | 1.01 Entry into a material agreement; 2.03 New direct financial obligation; 9.01 Financial statements and exhibits | 0001193125-25-133730 |
| 2025-06-0206:36 ET | 8-K | 7.01 Regulation FD disclosure; 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-25-132736 |
| 2025-05-1916:41 ET | 8-K | 5.07 Shareholder vote results | 0000950170-25-074446 |
| 2025-05-0718:22 ET | 10-Q | Quarterly reportPeriod 2025-03-31 | 0000950170-25-064733 |
| 2025-05-0608:00 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0000950170-25-063975 |
| 2025-04-0316:06 ET | DEF 14A | Proxy statementPeriod 2025-05-14 | 0001140361-25-012034 |
| 2025-02-2816:00 ET | 10-K | Annual reportPeriod 2024-12-31 | 0000950170-25-029969 |
| 2025-02-2608:00 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0000950170-25-027337 |
| 2025-01-1308:06 ET | 8-K | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001193125-25-005010 |
| 2024-11-0716:00 ET | 10-Q | Quarterly reportPeriod 2024-09-30 | 0000950170-24-123239 |
| 2024-11-0708:00 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0000950170-24-122814 |
| 2024-11-0419:49 ET | SC 13D/A | Ownership report, active investor, amended | 0001193125-24-250796 |
| 2024-10-3106:05 ET | 8-K | 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-24-248079 |
| 2024-10-2817:30 ET | 8-K | 2.02 Results of operations; 7.01 Regulation FD disclosure; 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-24-245704 |
| 2024-10-0209:01 ET | 8-K | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001193125-24-230760 |
| 2024-08-0816:36 ET | 10-Q | Quarterly reportPeriod 2024-06-30 | 0000950170-24-094108 |
| 2024-08-0808:00 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0000950170-24-093342 |
| 2024-07-0216:05 ET | 8-K | 5.02 Departure or appointment of officers or directors; 9.01 Financial statements and exhibits | 0001193125-24-174318 |
| 2024-06-1216:05 ET | 8-K | 5.02 Departure or appointment of officers or directors | 0001193125-24-159935 |
| 2024-05-1717:15 ET | 8-K | 5.07 Shareholder vote results | 0000950170-24-061872 |
| 2024-05-1017:40 ET | 10-Q | Quarterly reportPeriod 2024-03-31 | 0000950170-24-057292 |
| 2024-05-0907:30 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0000950170-24-056283 |
| 2024-04-0317:00 ET | DEF 14A | Proxy statementPeriod 2024-05-15 | 0001140361-24-017650 |
| 2024-03-2720:35 ET | 10-K | Annual reportPeriod 2023-12-31 | 0000950170-24-036729 |
| 2024-03-2619:57 ET | SC 13D/A | Ownership report, active investor, amended | 0001104659-24-039188 |
| 2024-03-2007:30 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0000950170-24-033947 |
| 2024-02-2019:11 ET | SC 13D/A | Ownership report, active investor, amended | 0001104659-24-025676 |
Source: SEC EDGAR, the company’s filing index. Last ingested by Listed: Oct 24, 2026, 15:15 ET. Listed shows no prices and gives no investment advice.